BioLineRx (NASDAQ:BLRX) Rating Increased to Sell at StockNews.com

BioLineRx (NASDAQ:BLRX - Get Free Report) was upgraded by research analysts at StockNews.com to a "sell" rating in a report released on Friday.

Separately, HC Wainwright reaffirmed a "buy" rating and set a $21.00 price objective on shares of BioLineRx in a report on Tuesday, March 26th.

BioLineRx Stock Performance

Shares of NASDAQ:BLRX traded up $0.02 during midday trading on Friday, hitting $0.72. The company had a trading volume of 542,698 shares, compared to its average volume of 398,197. The company has a market cap of $51.95 million, a price-to-earnings ratio of -0.80 and a beta of 1.38. The company has a fifty day moving average of $1.11 and a two-hundred day moving average of $1.37. BioLineRx has a 12-month low of $0.65 and a 12-month high of $2.53. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.53 and a quick ratio of 1.47.

BioLineRx (NASDAQ:BLRX - Get Free Report) last issued its quarterly earnings data on Thursday, March 28th. The biotechnology company reported ($0.15) earnings per share for the quarter, beating analysts' consensus estimates of ($0.22) by $0.07. The firm had revenue of $4.80 million for the quarter, compared to analysts' expectations of $0.17 million. During the same quarter in the previous year, the business earned ($0.09) EPS. On average, equities research analysts expect that BioLineRx will post -1.03 EPS for the current fiscal year.

Institutional Trading of BioLineRx

Several hedge funds have recently modified their holdings of BLRX. Renaissance Technologies LLC raised its holdings in shares of BioLineRx by 278.0% during the 4th quarter. Renaissance Technologies LLC now owns 257,900 shares of the biotechnology company's stock worth $152,000 after acquiring an additional 189,678 shares in the last quarter. Atria Wealth Solutions Inc. purchased a new stake in BioLineRx during the 1st quarter valued at $178,000. Envestnet Asset Management Inc. purchased a new stake in BioLineRx during the 1st quarter valued at $88,000. LPL Financial LLC raised its holdings in BioLineRx by 152.7% during the 4th quarter. LPL Financial LLC now owns 117,710 shares of the biotechnology company's stock valued at $69,000 after buying an additional 71,134 shares during the period. Finally, PVG Asset Management Corp purchased a new stake in BioLineRx during the 4th quarter valued at $97,000. 1.56% of the stock is owned by hedge funds and other institutional investors.

About BioLineRx

BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.